Item
5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On May 8,
2008, SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”)
entered into a Change in Control Agreement with Ivan Hui, Assistant Vice
President, Finance (the “Change in Control Agreement”). Pursuant to the
Change in Control Agreement, in the event Mr. Hui is involuntarily terminated
within one year following a change in control of the Company (as defined in such
agreement), he will be entitled to severance pay equal to seventy-five percent
(75%) of his annual base salary as in effect at the time of such termination,
the immediate vesting of any then-unvested portion of his options to purchase
shares of Common Stock of the Company and certain health care benefits. If
Mr. Hui voluntarily resigns or is terminated for cause, he will not be
entitled to any severance pay or benefits under the Change in Control
Agreement.
The
foregoing description of the terms and conditions of the Change in Control
Agreement is qualified in its entirety by the actual terms and conditions of the
Change in Control Agreement as attached as Exhibit 99.1 to this Current Report
on Form 8-K.
Item
9.01. Financial Statements and Exhibits
(a)
Financial statements:
None
(b)
Pro forma financial information:
None
(c)
Shell company transactions:
None
(d)
Exhibits
The
following exhibit is included with this Current Report on Form 8-K:
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Change
in Control Agreement between SciClone Pharmaceuticals, Inc. and
Ivan Hui dated and effective as of May 8,
2008.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Dated:
May 9, 2008
|
SCICLONE
PHARMACEUTICALS, INC.
|
||
|
By:
|
/s/ Friedhelm
Blobel
|
||
|
Friedhelm
Blobel, Ph.D.
|
|||
|
President
& Chief Executive Officer and Acting Chief Financial Officer
(Principal Financial Officer)
|
|||
Exhibit
Index
|
Exhibit
No.
|
Description
|
|
|
Change
in Control Agreement between SciClone Pharmaceuticals, Inc. and
Ivan Hui dated and effective as of May 8,
2008.
|